Shares of Moderna jumped more than 8% in after-hours trading Tuesday following the pharmaceutical company’s announcement of a deal to resolve a patent dispute related to its COVID vaccine. The agreement is expected to clear the way for continued progress in Moderna’s vaccine pipeline.
Resolving the Dispute
The specifics of the dispute and the terms of the resolution were not detailed in the announcement. However, Moderna indicated that reaching a deal provides “certainty” for its vaccine development efforts. This suggests the dispute had been creating some level of uncertainty regarding the company’s future projects.
Implications for Moderna’s Pipeline
Moderna has a broad vaccine portfolio under development, including vaccines for COVID-19, RSV, flu, CMV, EBV, HIV, Lyme disease, Nipah and Mpox. The company is also pursuing oncology therapeutics. As of January 12, 2025, Moderna had several programs in Phase 3 clinical trials, including vaccines for COVID-19, RSV, flu, and norovirus.
What’s Next
Moderna will now be able to accelerate the development and clinical trials of its various vaccine candidates. Analysts expect the company to continue focusing on its respiratory vaccine portfolio, with a possible U.S. Launch of its RSV vaccine following FDA approval and ACIP recommendation in 2024. Further Phase 3 readouts are anticipated in 2024, including for a combination flu and COVID-19 vaccine and a CMV vaccine.
Frequently Asked Questions
What types of vaccines is Moderna developing?
Moderna is developing vaccines for a wide range of diseases and conditions, including COVID-19, RSV, flu, CMV, EBV, HIV, Lyme disease, Nipah, and Mpox.
What phase are Moderna’s vaccine programs in?
Moderna has programs in Phase 1, Phase 2, and Phase 3 clinical trials, as well as some vaccines that are already commercially available, such as the COVID-19 vaccine SPIKEVAX.
What is the significance of the patent dispute resolution?
The resolution provides “certainty” for Moderna’s vaccine portfolio, allowing the company to focus on the development and commercialization of its vaccines.
How might this resolution impact the future availability of vaccines for various diseases?
